Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
104 hedge funds and large institutions have $633M invested in Infinity Pharmaceuticals, Inc. in 2013 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 34 increasing their positions, 33 reducing their positions, and 20 closing their positions.
20% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 20
4% more funds holding
Funds holding: 100 → 104 (+4)
3% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 33
2% less call options, than puts
Call options by funds: $13.7M | Put options by funds: $13.9M
24% less capital invested
Capital invested by funds: $835M → $633M (-$202M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$25.6M |
| 2 |
Goldman Sachs
New York
|
+$19M |
| 3 |
VAM
Visium Asset Management
New York
|
+$13.4M |
| 4 |
BC
Broadfin Capital
New York
|
+$9.97M |
| 5 |
Renaissance Technologies
New York
|
+$7.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$38.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$36.2M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$10.2M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$9.07M |
| 5 |
QF
QVT Financial
New York
|
-$8.55M |
INFI Hedge Fund Activity: Q4 2013 in Review
104 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q4 2013, worth a combined $633M — down 24% from $835M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new INFI positions and 20 closed out — a net gain of 4 holders — while 34 added to existing stakes and 33 trimmed.
The largest buyer was Deerfield Management, adding an estimated $25.6M. The largest seller was Fidelity Investments, cutting an estimated $38.4M.
- 104 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q4 2013, up from 100 in Q3 2013.
- Funds reported $633M of Infinity Pharmaceuticals, Inc. stock for Q4 2013, down 24% quarter-over-quarter.
- 24 funds opened new Infinity Pharmaceuticals, Inc. positions in Q4 2013 and 20 closed out, a net change of +4 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q4 2013 was Deerfield Management, an estimated $25.6M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q4 2013 was Fidelity Investments, an estimated $38.4M sold.
Based on aggregated 13F filings for Q4 2013.